Resumo

ROQUE-GARCIA, Wilfredo; ALMAGRO-VAZQUEZ, Delfina; CASTILLO-GONZALEZ, Dunia  e  AGRAMONTE-LLANES, Olga. High-dose dexamethasone in chronic primary immune thrombocytopenia. Rev Cubana Hematol Inmunol Hemoter [online]. 2012, vol.28, n.4, pp. 404-415. ISSN 0864-0289.

A prospective, analytical and applied study was conducted to determine the effectiveness of treatment with high-dose dexamethasone in patients with chronic primary immune thrombocytopenia, who were assisted at the Hemostasis service of the Institute of Hematology and Immunology from April 2008 to April 2011. 30 patients, 18 females and 12 males with an average age of 37 years were studied. Favorable response was achieved in 17 patients (68.0%), out of them, 14 had complete and 3 had partial remission respectively. No response was obtained in eight patients. A significant increase in platelet count was observed during the whole therapy. Referrals are obtained early, from the first to the third cycle, and late responses were not observed. Most patients who responded to previous treatment with prednisone had a favorable response to dexamethasone. In general, adverse events were mild and the most frequent were myalgia, edema, and arthralgias. Three patients required stopping the treatment because of side effects and nine maintained remission during the follow-up period. High-dose dexamethasone is an effective and safe alternative treatment in patients with chronic primary immune thrombocytopenia.

Palavras-chave : immune thrombocytopenia; prednisone; dexamethasone.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )